1. INTRODUCTION
===============

Breast cancer is the most common form of cancer affecting women in Canada, with more than 22,200 new cases being diagnosed and 5300 deaths occurring annually [@b1-co16-6-393]. Early breast cancer ([ebc]{.smallcaps}) is considered to be a potentially curable disease. Surgery remains the definitive treatment for [ebc]{.smallcaps}. Adjuvant systemic therapy, such as chemotherapy or hormonal treatment, is administered depending upon stage, grade, and other tumour characteristics.

In premenopausal women, adjuvant chemotherapy reduces the risk of disease relapse by 37% and of death by 30%. For women aged 50 to 69 years, the risk reductions are 19% (relapse) and 12% (death). The conferred absolute gain in survival appears to depend on the magnitude of risk of recurrence at presentation [@b2-co16-6-393].

To achieve the full benefit of chemotherapy in potentially curable [ebc]{.smallcaps}, maintaining dose intensity is very important. In chemotherapy regimens, there is good evidence for a threshold of delivered relative dose intensity ([rdi]{.smallcaps}), below which the clinical benefits may become compromised [@b3-co16-6-393]. Many clinicians and quality assurance programs have adopted the [rdi]{.smallcaps} criterion of Bonadonna *et al.* in adjuvant chemotherapy for [ebc]{.smallcaps} [@b3-co16-6-393].

The benefit of maintaining dose intensity is not limited to breast cancer. Trials in non-Hodgkin lymphoma ([nhl]{.smallcaps}) have demonstrated similar improvements in disease-free survival and overall survival if dose intensity is maintained above a certain level [@b4-co16-6-393],[@b5-co16-6-393].

Despite the fact that maintaining [rdi]{.smallcaps} is important to achieve improved outcome, many patients in adjuvant settings are treated with a lower dose intensity of chemotherapy. Lyman *et al.* reported a survey of more than 20,000 women with [ebc]{.smallcaps}, which showed that 55% of women received less than 85% of the [rdi]{.smallcaps} [@b6-co16-6-393]. A similar trend of dose reduction was reported in more than 4500 patients with aggressive [nhl]{.smallcaps}. In that survey, dose reductions of 15% or more occurred in 40% of patients, and treatment delays up to 7 days occurred in 24% of patients [@b7-co16-6-393]. Most of the patients in the [ebc]{.smallcaps} study reported by Lyman *et al.* [@b6-co16-6-393] received [cmf]{.smallcaps} \[cyclophosphamide, methotrexate, 5-fluorouracil (5[fu]{.smallcaps})\], [caf]{.smallcaps} (cyclophosphamide, doxorubicin, 5[fu]{.smallcaps}), or [ac]{.smallcaps} \[doxorubicin (Adriamycin: Pharmacia, Kalamazoo, MI, U.S.A.), cyclophosphamide\] chemotherapy regimens, which are now less frequently used for adjuvant treatment of [ebc]{.smallcaps}.

Considering the importance of maintaining dose intensity in the adjuvant setting [@b8-co16-6-393], we conducted a retrospective analysis in patients with [ebc]{.smallcaps} treated at a Canadian centre with adjuvant chemotherapy consisting of [fec-]{.smallcaps}100 (5[fu]{.smallcaps}--epirubicin--cyclophosphamide), [ac-t]{.smallcaps} \[doxorubicin (Adriamycin)--cyclophosphamide, paclitaxel (Taxol: Bristol--Myers Squibb, Princeton, NJ, U.S.A.)\], or [fec-d]{.smallcaps} (5[fu]{.smallcaps}--epirubicin--cyclophosphamide, docetaxel). We also analyzed the incidence of febrile neutropenia in this patient population. Here, we report our experience with delivered [rdi]{.smallcaps} in these patients receiving the most recent generation of adjuvant chemotherapy regimens.

2. PATIENTS AND METHODS
=======================

After obtaining local ethics board permission to conduct the study, data were collected retrospectively in a chart review of 275 [ebc]{.smallcaps} patients treated from January 2006 to November 2007 at the London Regional Cancer Program, London, Ontario, Canada. Chart data was extracted only for those patients ([Table I](#tI-co16-6-393){ref-type="table"}) who were treated with one of the following regimens: [ac-t]{.smallcaps} (4 cycles of doxorubicin--cyclophosphamide, followed by 4 cycles of paclitaxel, all given once every 3 weeks), [fec-]{.smallcaps}100 (6 cycles of 5[fu]{.smallcaps}--epirubicin--cyclophosphamide, once every 3 weeks), or [fec-d]{.smallcaps} (3 cycles of [fec-]{.smallcaps}100 followed by 3 cycles of docetaxel, all given once every 3 weeks).

Data collection included pretreatment demographics and clinical characteristics, particularly age at diagnosis, chemotherapy regimen, and planned dose and schedule. All episodes of febrile neutropenia were also recorded for each patient across all cycles.

The primary objective was to calculate the delivered [rdi]{.smallcaps}, defined as the proportion actually received of the reference standard dose intensity for each regimen. The numbers of patients receiving less or more than 85% of the [rdi]{.smallcaps} were recorded separately. Incidences of chemotherapy dose delays of more than 7 days or dose reductions of more than 15% were recorded for all chemotherapy cycles.

Summative dose intensity ([sdi]{.smallcaps}) is a concept applied to clinical trials in which the relationships of dose intensity with effects are studied. The [sdi]{.smallcaps} is defined as the sum of the contributions of individual drug dose intensities in a combination drug regimen, and here, it is calculated based on the work of Hryniuk *et al.* [@b12-co16-6-393] Hryniuk *et al.* showed a positive relationship between higher dose intensities and better outcomes in patients with [ebc]{.smallcaps}, and those data have served as the groundwork for many trials starting in the late 1980s.

The [sdi]{.smallcaps} of each regimen is calculated in four steps:

-   First, a unit dose intensity ([udi]{.smallcaps}---the dose of the drug required to produce 30% complete responses, plus partial responses, when used as a first-line single-agent chemotherapy in metastatic breast cancer) is calculated for each drug in the combination regimen. The [udi]{.smallcaps}s for 5[fu]{.smallcaps}, epirubicin, and cyclophosphamide are 650, 25, and 700 respectively.

-   In the second step, the dose intensity of each drug in a combination is expressed as a fraction of it own [udi]{.smallcaps}. The individual dose in milligrams per square metre body surface area is converted to a per-week fraction. For example, in the [fec-]{.smallcaps}100 regimen, cyclophosphamide and 5[fu]{.smallcaps} at 500 mg/m^2^ every 3 weeks becomes 167/week, and epirubicin at 100 mg/m^2^ every 3 weeks becomes 33.33/week.

-   In the third step, the calculated weekly standard dose from step 2 is divided by the [udi]{.smallcaps} from step 1 to yield the [sdi]{.smallcaps} of the individual drug ([Table II](#tII-co16-6-393){ref-type="table"} shows the [sdi]{.smallcaps}s of the studied regimens). For example, for 5[fu]{.smallcaps}, 167/650 produces an [sdi]{.smallcaps} of 0.26. The corresponding results for epirubicin and cyclophosphamide are 1.33 and 0.23 respectively.

-   In the last step, the [sdi]{.smallcaps}s of the regimen are summed. For [fec-]{.smallcaps}100, the final [sdi]{.smallcaps} is therefore 1.82.

If a patient experiences a dose reduction of 25% in 6 cycles of [fec-]{.smallcaps}100, the drop for the total dose of 5[fu]{.smallcaps} would be to 2250 mg/m^2^ from 3000 mg/m^2^ over 18 weeks. The corresponding dose intensity would be calculated at 125/week to yield a final [sdi]{.smallcaps} of 0.178. In this case scenario, the [sdi]{.smallcaps}s for epirubicin and cyclophosphamide would be 1 and 0.192, thereby delivering a 1.37 [sdi]{.smallcaps} for the regimen. Thus, with this reduction in the dose, the delivered [rdi]{.smallcaps} is 1.37/1.82 (about 75%). In randomized trials in which dose intensity is tested, response rates and survival were linearly associated with the [sdi]{.smallcaps} in each treatment arm [@b6-co16-6-393].

3. RESULTS
==========

Of the 263 evaluable patients, 98 received [fec-d]{.smallcaps}; 100, [ac-t]{.smallcaps}; and 65, [fec-]{.smallcaps}100. Overall, 14.4% of the patients experienced a dose delay of 1 week or more, and 22% experienced a dose reduction of any degree ([Table I](#tI-co16-6-393){ref-type="table"}). About 33% of all patients experienced either dose reduction or dose delay, but overall only 14.4% received less than 85% of the [rdi]{.smallcaps}.

Dose delays were noted in 25%, 13%, and 0% of patients receiving [ac-t]{.smallcaps}, [fec-d]{.smallcaps}, and [fec-]{.smallcaps}100 respectively, and dose reductions were noted in 18%, 10.2%, and 46% respectively. Dose delay or reduction was found in 46% of patients treated with [fec-]{.smallcaps}100, in 37% treated with [ac-t]{.smallcaps}, and in 20% treated with [fec-d]{.smallcaps}. The delivered [rdi]{.smallcaps} was above 85% in 96%, 95%, and 70.7% of the [ac-t]{.smallcaps}, [fec-d]{.smallcaps}, and [fec-]{.smallcaps}100 regimens ([Figure 1](#f1-co16-6-393){ref-type="fig"}).

In our study population, 14% patients were 65 years of age or older. Of the patients treated with [fec-]{.smallcaps}100, 33.8% were over 65 years of age as compared with 8.2% of patients treated with [fec-d]{.smallcaps} and 7% treated with [ac-t]{.smallcaps}.

The delivered [rdi]{.smallcaps} was less than 85% in approximately 35% of patients 65 years of age or older, as compared with 6.6% of patients younger than 65 years of age. Overall, for the 65-or-older age group, the incidence of febrile neutropenia was 27% as compared with 16.3% for patients under 65 years of age ([Figure 2](#f2-co16-6-393){ref-type="fig"}). The overall incidence of febrile neutropenia was 17.8%, being observed at rates of 26.1%, 23.4%, and 7% in the [fec-]{.smallcaps}100, [fec-d]{.smallcaps}, and [ac-t]{.smallcaps} regimens respectively ([Figure 3](#f3-co16-6-393){ref-type="fig"}). Most of the febrile neutropenia episodes in patients treated with the [fec-d]{.smallcaps} regimen (19 of 23) coincided with the first cycle of docetaxel.

4. DISCUSSION AND CONCLUSIONS
=============================

4.1 Delivered RDI
-----------------

We analyzed data for patients receiving three frequently used adjuvant chemotherapy regimens for [ebc]{.smallcaps}, utilizing appropriate methods to calculate the delivered [rdi]{.smallcaps}s. Considering the importance of [rdi]{.smallcaps}, we hope that our data will help other physicians to calculate [rdi]{.smallcaps} for their patients. Data from previously published trials demonstrate that [ebc]{.smallcaps} patients treated with adjuvant chemotherapy are at considerable risk of reduced delivered [rdi]{.smallcaps} [@b6-co16-6-393],[@b7-co16-6-393]. However, our data analysis has been encouraging: It showed that the [rdi]{.smallcaps} received by most of our patients exceeded 85%.

This result is likely attributable to multiple factors. Our medical oncology group adheres to breast cancer treatment guidelines when evaluating systemic therapy plans for patients with [ebc]{.smallcaps}. There is general awareness among medical oncologists about the importance of the relationship between dose intensity and outcome in [ebc]{.smallcaps}. Several previous trials have provided data showing improved outcomes with maintenance of [rdi]{.smallcaps} during adjuvant chemotherapy for [ebc]{.smallcaps} [@b13-co16-6-393],[@b14-co16-6-393]. A 20% dose reduction may compromise cure by 50%, and patients receiving less than 65% dose intensity are expected to have a survival similar to that of an untreated control group [@b15-co16-6-393]. Randomized clinical trials have shown that granulocyte colony--stimulating factor ([g-csf]{.smallcaps}) can reduce the risk of complications associated with chemotherapy and also facilitate the delivery of full-dose [rdi]{.smallcaps} [@b16-co16-6-393]. The accessibility and more frequent use of growth factors could be another reason behind our results. For the patients reviewed here, the use of [g-csf]{.smallcaps} was limited to patients with documented febrile neutropenia, and none of the patients was treated with [g-csf]{.smallcaps} as primary prophylaxis. Earlier surveys showing a lower delivered [rdi]{.smallcaps} in [ebc]{.smallcaps} patients focussed on community medical oncology practices. Our centre, being an academic cancer centre, may certainly have had a different approach to managing patients from the perspective both of the physicians and the nursing staff and of resources, accounting for a different outcome.

4.2 Occurrence and Management of Febrile Neutropenia
----------------------------------------------------

Generally, elderly women are considered to be more prone to chemotherapy-related side effects, including febrile neutropenia, which may have translated to a reduced [rdi]{.smallcaps} for this group of women within the study sample. Among [fec-]{.smallcaps}100 treated patients, the incidence of febrile neutropenia was high, and more frequently, these patients received a lesser [rdi]{.smallcaps}. However, a relatively smaller number of patients were treated with the [fec-]{.smallcaps}100 regimen. These findings correlate well with the fact that 34% of patients treated with the [fec-]{.smallcaps}100 regimen were more than 65 years of age (compared with 16% and 7% of the patients treated with [fec-d]{.smallcaps} and [ac-t]{.smallcaps}). In addition, the [fec-]{.smallcaps}100 recipients appeared to have more comorbid illnesses than did patients receiving other adjuvant combination chemotherapy.

The [fec-d]{.smallcaps} regimen is an effective, relatively new, but quite frequently-used combination for [ebc]{.smallcaps} in the adjuvant setting. The reported incidence of febrile neutropenia with [fec-d]{.smallcaps} in the [pacs]{.smallcaps} 01 trial (Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients) was around 11% [@b10-co16-6-393]; however, our experience shows a higher risk of febrile neutropenia (23%). Interestingly, most of the febrile neutropenia incidences were reported with the first dose of docetaxel (cycle 4), consistent with the observations in the [pacs]{.smallcaps} 01 trial. Other Canadian cancer centres have experienced similar trends in the incidence of febrile neutropenia with the [fec-d]{.smallcaps} regimen (Ottawa and Sudbury cancer centres. Personal communication). With such a high rate of febrile neutropenia, we should consider giving [g-csf]{.smallcaps} as primary prophylaxis with [fec-d]{.smallcaps}, possibly starting from cycle 1, but at least for the last 3 cycles.

4.3 Study Limitations
---------------------

The present study is limited by its retrospective design and small sample size. However, we feel that it still represents a reasonable cross-sectional view of the management of [ebc]{.smallcaps} in a Canadian academic cancer centre. The three regimens analyzed were in use at different times. The [ac-t]{.smallcaps} combination was used between 2001 and 2004, and many patients included in the review were part of the National Cancer Institute of Canada Clinical Trials Group [ma.]{.smallcaps}21 trial. Thus a potential selection bias related to those patients may be present. The [fec-]{.smallcaps}100 regimen came into use around 2005 and was initially believed to be carrying relatively fewer side effects. That belief may have contributed more elderly patients to that group. The [fec-d]{.smallcaps} regimen is the newest and has been particularly used in lymph-node-positive patients. Thus, almost a decade has gone into the selection of these patients, and changes in physician practices, guidelines, and other factors may potentially have injected some biases into the outcomes reported.

4.4 Summary
-----------

We hope that these data can help physicians to become more aware of the importance of maintaining optimal dose intensities for adjuvant chemotherapy treatment in [ebc]{.smallcaps}. We believe that improvements in the overall management of such patients will lead to doses in the frequently used chemotherapy regimens being maintained close to the optimal [rdi]{.smallcaps}. Because elderly patients derive benefits from the use of adjuvant chemotherapy similar to those seen in their younger peers, particular attention should be paid to the need to improve delivered [rdi]{.smallcaps} in the elderly patient population. A proactive role to address chemotherapy-related side effects and the use of [g-csf]{.smallcaps} may help to achieve that goal.
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###### 

Characteristics of the treatment received by the study patients

  Treatment characteristic            Overall (*N =* 263)   Patients Age\<65 (86%)   Age ≥65 (14%)
  ----------------------------------- --------------------- ------------------------ ---------------
  [ac/t]{.smallcaps}                  *n=*100               93%                      7%
  [fec]{.smallcaps}/[d]{.smallcaps}   *n=*98                91.8%                    8.2%
  [fec]{.smallcaps} 100               *n=*65                66.1%                    33.9%
  [rdi]{.smallcaps} \> 85%            89.9%                 93.3%                    64.8%
  Dose delay \> 7 days                14.4%                 15%                      10.8%
  Dose reduction                      22%                   16.8%                    54%

[rdi]{.smallcaps} = relative dose intensity.

###### 

Chemotherapy regimens: reference standard dose, schedule, and summative dose intensity ([sdi]{.smallcaps})

                                                   [ac/t]{.smallcaps}[@b9-co16-6-393] (*n*=100)   [fec/d]{.smallcaps}[@b10-co16-6-393] (*n*=100)   [fec]{.smallcaps} 100 [@b11-co16-6-393] (*n*=75)
  ------------------------------------------------ ---------------------------------------------- ------------------------------------------------ --------------------------------------------------
  Cycle length (days)                              21                                             21                                               21
  Doxorubicin \[[a]{.smallcaps} (mg/m^2^)\]        60                                                                                              
  Cyclophosphamide \[[c]{.smallcaps} (mg/m^2^)\]   600                                            500                                              500
  Paclitaxel \[[t]{.smallcaps} (mg/m^2^)\]         175                                                                                             
  Fluorouracil \[[f]{.smallcaps} (mg/m^2^)\]                                                      500                                              500
  Docetaxel \[[d]{.smallcaps} (mg/m^2^)\]                                                         100                                              
  Cycles given (*n*)                               [ac]{.smallcaps}×4, [t]{.smallcaps}×4          [fec]{.smallcaps}×3, [d]{.smallcaps}×4           [fec]{.smallcaps}×6
  [sdi]{.smallcaps}                                3                                              3.8                                              1.8
